Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
Keep Reading →
August 30 - News
Many market watchers believe that quarterly 13F filings from hedge funds are of no use to most investors, but we have shown that this is false in at least one way: it is possible...
Keep Reading →
August 29 - Dividend Stocks, Hedge Funds
In an attempt to further simplify its business and unlock shareholder value, Pfizer Inc. (NYSE:PFE) has been busy divesting itself of non-core assets.
Keep Reading →
August 29 - News
In the 21st century investor’s toolkit, there are dozens of methods market participants can use to monitor the equity markets.
Keep Reading →
August 29 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 28 - News
ViiV Healthcare -- a joint venture by Pfizer Inc.
Keep Reading →
August 28 - News
At the same time, the pharmaceutical industry isn't without its share of risks.
Keep Reading →
August 28 - News
We maintain a database of quarterly 13F filings from hundreds of hedge funds and other notable investors.
Keep Reading →
August 27 - Hedge Funds
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
Keep Reading →
August 26 - News
Every investor has heard the old line "sell in May and go away." That wasn't such great advice this year with the S&P 500 index up nearly 5% since the beginning of May.
Keep Reading →
August 26 - News
Organovo Holdings Inc (NYSEMKT:ONVO) is a little company that people think could do big things.
Keep Reading →
August 25 - News
At StreetAuthority, we often look at where Washington's most powerful men are putting their money.
Keep Reading →
August 23 - News
Editor’s Note: A previous version of this post incorrectly stated that Eli Lilly’s experimental drug solanezumab is a BACE inhibitor.
Keep Reading →
August 23 - News
To the average investor, there are plenty of gauges investors can use to track Mr. Market. Some of the most useful are hedge fund and insider trading interest.
Keep Reading →
August 22 - News
One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK inhibitors.
Keep Reading →
August 22 - News
Imagine a day where there are no waiting lists for liver transplants. Instead, patients can have a perfectly tailored liver bioprinted and placed into their body.
Keep Reading →
August 21 - News
Now, according to many traders, hedge funds are seen as delayed, outdated investment tools of an era lost to time.
Keep Reading →
August 21 - News
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Keep Reading →
August 21 - News
Opinions rage about whether health insurance costs will rise or fall with implementation of the Affordable Care Act, commonly known as Obamacare.
Keep Reading →
August 19 - News
This could have been an enormously more difficult effort. I started out with the goal to identify the three best stocks in health care to buy and hold for years, even decades.
Keep Reading →
August 19 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 19 - News
Last week, the Trust for America's Health and the Robert Wood Johnson Foundation released their annual report (link opens a PDF to a 116-page report) on obesity trends in the ...
Keep Reading →
August 19 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 16 - News
MannKind Corporation (NASDAQ:MNKD) ended up more than 10% on Wednesday, after the biotech announced positive results for two phase 3 trials testing its inhaled insulin Afrezza...
Keep Reading →
August 15 - News
In August, billionaire Stanley Druckenmiller’s family office (Druckenmiller is the former head of Duquesne Capital) filed its 13F for the second quarter of 2013 with the SEC...
Keep Reading →
August 15 - Hedge Funds
The long promise of insulin that diabetics can inhale appears to be moving closer to the market.
Keep Reading →
August 14 - News
Ever since August 2011, I've been calling out one or two companies every month that I was putting my own retirement money behind.
Keep Reading →
August 13 - News
The ideal situation for a spinoff is when you have a small, fast growing division lodged within a large, slower-growing company.
Keep Reading →
August 12 - News
With the full implementation of the individual portion of the Patient Protection and Affordable Care Act less than five months away, physicians and doctor's offices around the...
Keep Reading →
August 12 - News
I don't know which is worse: The fact that insider trading was legal for some of our nation's wealthiest politicians...
Keep Reading →
August 12 - News
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Keep Reading →
August 12 - News
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc.
Keep Reading →
August 7 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
August 7 - News
In America, 33.5% of adults over the age of 20 have high LDL (“bad”) cholesterol levels, according to the CDC.
Keep Reading →
August 7 - News
A recent EvaluatePharma report estimated the market for prescribed drugs will increase at an annual rate of 3.8% to $895 billion from 2012 to 2018.
Keep Reading →
August 6 - News
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been stuck is share purgatory for a number of years.
Keep Reading →
August 6 - News
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
Keep Reading →
August 6 - News
Chronic obstructive pulmonary disease (COPD) is America’s third leading cause of death.
Keep Reading →
August 5 - News
Zoetis will release its quarterly report on Tuesday, and investors will get their first look at the company as a completely independent business entity.
Keep Reading →
August 5 - News
The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive.
Keep Reading →
August 5 - News
During the past decade, healthcare has been one of the most stable and consistent performers among all industries.
Keep Reading →
August 5 - News
In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies.
Keep Reading →
August 3 - News
Budding biotech company Incyte Corporation (NASDAQ:INCY), which specializes in developing novel JAK inhibitors, released solid second-quarter earnings on Wednesday.
Keep Reading →
August 1 - News
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Keep Reading →
August 1 - News
High yields aren't everything when you're searching for the perfect dividend stock.
Keep Reading →
August 1 - News
The good news was that the big pharmaceutical company beat earnings estimates. Merck & Co., Inc.
Keep Reading →
July 31 - News
The company broke open a bombshell on Monday when it announced that it would break its business into three new divisions -- two focused around drugs, vaccines, and consumer products...
Keep Reading →
July 31 - News
Today, let's look at investing giant Donald Yacktman, who founded Yacktman Asset Management in 1992.
Keep Reading →
July 31 - Hedge Funds
So much for the stock market gains that dominated most of today's trading.
Keep Reading →
July 30 - News
This morning the Dow Jones Industrial Average (INDEXDJX:.DJI)'s two big drug companies and a number of smaller drug-related companies announced earnings.
Keep Reading →
July 30 - News